Related Experiment Video
Updated: Jan 8, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint
Matthew J Slaught1, Dalia Kaakour2, Armon Azizi1
1University of California Irvine School of Medicine, Irvine, CA, USA.
Aims:
To investigate the association between primary cancer type and the tissues affected by immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs).
Patients & Methods:
A retrospective chart review was conducted on 241 patients representing 262 treatment lines involving ICIs at a single institution.
Results:
No significant association was found between cancer type and tissue-specific irAEs. irAE incidence was higher with combination PD-1/CTLA-4 inhibitors vs. PD-1 inhibitors alone (61% vs. 46%, p = 0.042). Median time to first irAE was 7.88 months for PD-1 monotherapy versus 2.30 months for combination therapy (log-rank p = 0.00011), a difference of 5.58 months.
Conclusions:
Primary cancer type was not significantly associated with tissue-specific irAEs in ICI-treated patients. The 5.58-month difference in median time to irAE onset has important implications for monitoring protocols. Further research is needed to identify factors predicting irAE patterns and severity.
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...